cyrilzakka/clinical-trials huggingface dataset:
The WEB-IT Clinical Study

The study is a prospective, multicenter single-arm cohort. Patients with wide neck bifurcation aneurysms (WNBAs) have few choices for safe and effective endovascular treatment. In this study, all patients with qualifying WNBAs will be treated with the WEB. The primary effectiveness outcome of the study is the likelihood of complete intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.


Eligibility Criteria:
Inclusion Criteria:

* Patient whose age ≥18 and ≤75 years.
* Patient must have a single ruptured or unruptured IA (intracranial aneurysm) requiring treatment.
* Patient must sign and date an IRB/EC-approved written informed consent prior to initiation of any study procedures.

Exclusion Criteria:

* Patient has an IA with characteristics unsuitable for endovascular treatment
* Patient has stroke-in-evolution within the prior 60 days
* Patient has had an SAH (subarachnoid hemorrhage) from a nonindex IA or any other intracranial hemorrhage within 90 days
* Patient's index IA was previously treated
* Patient is pregnant
Effect of Lavender Inhalation on Dysmenorrhea

This study was planned to determine the effect of lavender inhalation on primary dysmenorrhea and its symptoms.

The research is a randomized controlled trial and an experimental research design will be used. The research will be carried out with two groups as experimental (lavender) and control (placebo) groups.

Eligibility Criteria:
Inclusion Criteria:

* Having primary dysmenorrhea (degrees II and III),
* Single,
* Who have never been pregnant before,
* Having a regular menstrual cycle
* Without any genital organ disorder (such as fibroids, fibroadenoma, endometriosis, metrorrhagia, ovarian cyst, pelvic inflammatory disease, chronic pelvic pain, other pelvic pathologies)
* Not using contraceptive method,
* Having a normal sense of smell
* People who can smell odors and are not allergic to odors will be included in the study.

Exclusion Criteria:

* Married,
* Having a disease that causes dysmenorrhea,
* Regularly using a pharmacological and non-pharmacological method to relieve
* Dysmenorrhea pain during the study,
* Having a previous or unconcluded pregnancy,
* Having a chronic disease (diabetes, endometriosis, uterine congenital anomalies, epilepsy, etc.),
* Using drugs that affect the menstrual cycle or dysmenorrhea,
* Persons who fill in the data collection form incompletely or not at all will not be included in the study.
PRostate Olaparib Real World Evidence Study

This French non-interventional prospective multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Adult male patients (≥ 18 years old)
* With metastatic castration-resistant prostate cancer - Who have initiated olaparib within the last two months of study entry, or for whom the decision to be treated with olaparib has been made by their physician
* Who have been informed and are not opposed to this data collection

Exclusion Criteria:

* Patients opposed to the collection of their data
* Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part.

Participants who were in the active arm in the double blind part and those who have completed OLE part in the parent study, will continue receive open-label gantenerumab 510 mg sub-cutaneously (SC) every 2 weeks (Q2W). Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme as in the parent study before receiving target dose of open label gantenerumab.

Eligibility Criteria:
Inclusion Criteria:

* Completed Study WN29922 or WN39658, either its double-blind part or OLE part, and did not discontinue study drug early
* The participant should be capable of completing assessments either alone or with the help of the caregiver
* Availability of a person (referred to as the "caregiver")
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception methods with a failure rate of \<1% per year (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the treatment period and for at least 16 weeks after the final dose of gantenerumab
* Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug

Exclusion Criteria:

* Pregnant or breastfeeding, or intending to become pregnant during the study or within at least 16 weeks after the final dose of study drug
* Prematurely discontinued from Study WN29922 or WN39658
* Any medical condition that may jeopardize the participant's safety if he or she continues to receive study treatment
* Received any investigational treatment other than gantenerumab during or since completion of Study WN29922 or WN39658, either its double-blind or OLE part
* Evidence of disseminated leptomeningeal hemosiderosis
* Evidence of intracerebral macrohemorrhage
* Use of prohibited medication
* Evidence of ARIA-E on the last MRI scan report in Study WN29922 or WN39658, either its double-blind or OLE part
A Structured School-based Health Intervention for the Obesity Prevention

The proposed research aims to assess how well a structured intervention is intended to reduce childhood obesity. The intervention addresses food and physical activity behaviors, important determinants of obesity, by concentrating on these elements. The goal of nutritional and physical education is to raise knowledge about the negative effects of obesity and encourage healthy eating habits in children and their caregivers. These educational campaigns will be delivered primarily through schools, guaranteeing a wide audience and consistent messaging.

The demographic profile of Pakistan offers a unique background for researching the dynamics of childhood obesity because of its rapid urban growth and socioeconomic shifts. Processed foods are displacing traditional diets, and children's physical activity is decreasing as a result of longer screen times and restricted access to leisure centers.

The proposed research aims to assess how well a structured intervention is intended to reduce childhood obesity. The intervention addresses food and physical activity behaviors, important determinants of obesity, by concentrating on these elements. Dietary Education: Teaches kids about eating the right portions of food and maintaining a balanced diet. Better eating habits and an understanding of nutrition are among the results.

Information regarding Physical Activity: Raises awareness and encourages regular exercise. Improved comprehension and engagement in physical activities are among the results.

Extra Physical Activity Time: Offers extra opportunities for physical activity after school, such as fitness classes and sports, after hours. Improved fitness, a decrease in sedentary time, and higher levels of physical activity are the results.

Eligibility Criteria:
Inclusion Criteria:

* Children of age between 5 to 12 years.
* Enrollment at one of the selected schools.

Exclusion Criteria:

* Children and their parents who did not give assent and consent to participate in the study.
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

This study is to evaluate available local data in Iraq patients with moderate-to-severe plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have difficult to treat sites at presentation.


Eligibility Criteria:
Inclusion Criteria:

* Moderate-to-severe plaque psoriasis patients whom have been receiving etanercept for at least 1 year duration.
* Have difficult to treat sites at presentation.
* Age ≥18 years.
* No history of using other biological treatments, other than etanercept for the treatment of moderate-to-severe PsO.

Exclusion Criteria:

* Etanercept use for treatment of moderate-to-severe PsO less than 1 year duration.
* Previous use of another biological treatment for treatment of moderate-to-severe PsO.
Assisted Hatching in Frozen Blastocysts

The current study aims to assess the effect of assisted hatching on the implantation rate of frozen blastocytes.

The Zona Pellucida protects the ovum from the penetration of multiple sperm, and from mechanical and physiological damage until the fertilized ovum reaches the uterus. Subsequently, spontaneous hatching occurs, and enables the embryo to attach to the endometrium. The technique of assisted hatching was originally investigated as a means to improve implantation in cases of zona hardening, and is commonly performed in 3-day embryos. In the current study, the investigators aim to investigate the effect of assisted hatching on 5-day frozen embryos.

Eligibility Criteria:
Inclusion Criteria:

* In-vitro fertilization patients at the investigators' institution, intended to undergo a transfer of a frozen five-day embryo (blastocyte)
* 18 to 39 years old
* First to third treatment cycle
* Patient has previously had a maximum of four embryos transferred.

Exclusion Criteria:

* Over 40 years old
* Congenital or acquired uterine malformations
* Hydrosalpinx
* Chronic autoimmune diseases
* Embryo intended to be undergo preimplantation genetic diagnosis
Reducing Energy Density by Different Methods to Decrease Energy Intake

The purpose of this research is to investigate how using different methods to reduce the energy density of entrees affects daily energy intake in adults. It is hypothesized that reducing the energy density of entrees will decrease energy intake. It is also hypothesized that reducing the energy density by incorporating fruit and vegetables will decrease energy intake more than reducing the energy density by decreasing fat content or adding plain water.


Eligibility Criteria:
Inclusion Criteria:

* Adults from Penn State and surrounding community

Exclusion Criteria:

* Currently dieting
* Food allergies
Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation

This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to take up the COVID-19 vaccine, recommend the vaccine, and also willingness to propagate the exposed message.


Eligibility Criteria:
Inclusion Criteria:

* Willing and able to give informed consent for participation in the trial
* Malaysian nationality.
* Can understand either the English or Malay language.
* Aged 18 years or above

Exclusion Criteria:

* Received at least one COVID-19 vaccination dose
Using Pulse Counter Vigileo-Flotrac System in Transapical Off-pump Minimally Invasive Mitral Valve Repair

Minimally invasive transapical off-pump chordae implantation includes features such as tachycardia, arrhythmia, hemorrhage, sudden hemodynamic changes caused by the device moving in the left ventricle and the atrium, for anesthetists. In this observational study, the investigators presented the investigators's hemodynamic recuperation and anesthesia experiences revealed by cardiac output measurement after transapical mitral valve repair.

In Sakarya University Educational Research Hospital, perioperative file records of 13 patients who underwent mitral valve repair using the Neochord DS1000 system were retrospectively analyzed. In addition, hemodynamic measurements recorded with the Vigileo Flotrac invasive arterial cardiac output device were evaluated.

Eligibility Criteria:
Inclusion Criteria:

* All patients that surgical criteria for Neochord implantation with transapical mini-thoracotomy are prolapsus or chordae rupture in posterior, anterior areas or in both leaflets were included.

Exclusion Criteria:

* Exclusion criteria are active endocarditis, functional or ischemic mitral insufficiency (MI), excessive calcific valves, leaflet perforation, anemic dilatation and severe left ventricular dysfunction.
Monkeypox ASymptomatic Shedding: Evaluation by Self-Sampling MPX-ASSESS

Monkeypox (MPX) is a viral zoonosis, caused by the Monkeypox virus (MPXV), a DNA virus that belongs to the Orthopoxvirus genus and is closely related to the variola virus, the causative agent of smallpox. Until recently the spread of MPX was mainly confined to the Central African rainforest and to parts of West Africa. However, in May 2022, several cases of MPX were detected throughout Europe and Northern America, albeit with a different presentation than previously seen. Many questions remain on this new presentation of the disease: what the exact mode of transmission is, how contagious the virus really is and whether asymptomatic carriers exist. With this study the researchers aim to perform a close follow-up study of close contacts of MPX confirmed cases. Participants are recruited among high and very high risk contacts of confirmed monkeypox patients that presented to the ITM for diagnosis (index). Contacts that are asymptomatic (for symptoms compatible with MPXV infection according to national case definitions) at the time of recruitment will be enrolled. Contacts of the index case that are symptomatic at recruitment or become symptomatic during follow-up will be invited for sample collection at different timepoints until 21 days after contact as suspect cases.


Eligibility Criteria:
Inclusion Criteria:

1. Be a high risk or very high-risk contact of a laboratory confirmed monkeypox case, with:

   * Very high-risk contact:

     * Sexual partner(s)
     * Prolonged skin-to-skin contact while the patient had skin lesions
   * High risk contact

     * living in the same household or similar environment (e.g. camping, spending the night, etc.);
     * shared clothing, bedding, utensils, etc., while the patient had skin lesions
     * healthcare workers with unprotected contact (inadequate or no PPE)
2. Last exposure to the monkeypox index case of less than 21 days ago
3. Adult participants (≥ 18 years old) of any gender
4. Written informed consent is obtained from the participant

Exclusion Criteria:

1. Presenting with symptoms compatible with MPX:

   * an unexplained rash on any part of the body AND
   * one or more of the following symptoms: fever, headache, back pain, fatigue, lymphadenopathy (localised or generalised)
2. Inability or unwillingness to comply with the proposed follow-up schedule
The Use of Proximal Carpal Row Versus Iliac Crest as Bone Graft in Total Wrist Fusion

Study purpose is to compare the outcome after total wrist arthrodesis (TWA) with proximal carpal row (Proximal Row Carpectomy = PRC) as bone graft versus iliac crest cancellous bone graft.

Patients with radiologically and clinically confirmed advanced osteoarthritis are randomized (1:1 computer generated sequence with random block size) to two parallel groups and will undergo either total wrist arthrodesis with PRC or TWA with iliac crest bone grafting.

Baseline data is collected preoperatively and is a follow-up visits at every 6 weeks after the surgery is arranged until the wrist is fused. The primary end-point is 6 months and the primary outcome is fusion rate.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 - 75
* Symptom duration \> 3 months
* American Society of Anaesthesiologists physical status (ASA) I-III
* Fluent in written and spoken Finnish

Exclusion Criteria:

* Age \<18 or \>75 years
* Rheumatoid arthritis
* Heavy smoking (\> 20 cigarettes per day)
* Condition or medication affecting bony healing (eg diabetes mellitus with poor glycemic control, malnutrition, use of per oral corticosteroids)
* Ulnar variance \> 1 mm
* Wrist pain treatable with partial wrist fusion
* Previous partial wrist fusion
* Alcohol or drug abuse
* Neurological condition affecting upper limb function
* Less than 6 months after another operation of the same upper limb
PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers

The purpose of this study is to investigate the radiotracer \[11C\] PIB in participants with probably Alzheimer's Disease (AD) and healthy age-matched controls.

The objectives of the study are:

1. To perform PET scans with \[11C\]PIB to use for direct (i.e., same-subjects) comparison of \[11C\]PIB and \[18F\]AV-45
2. To establish the most effective and reliable PET imaging method to detect amyloid deposition in AD, in order to understand disease progression and subsequently evaluate treatment effects.
3. To ascertain a PET imaging method that will minimize discomfort for subjects, thus increasing the potential for clinical follow-up scans, by reducing the patient burden and potential cost of future PET examinations.

A separate protocol/study will be conducted using \[18F\] AV-45. Participants who enroll in this protocol using \[11C\] PIB will be consented to participate in the \[18F\] AV-45 (IRB # NA_00033155) protocol/study as it is a mandatory requirement that participants participate in both protocols.Up to 20 participants with mild to moderate Alzheimer's Disease and 10 healthy volunteers will participate in this study.

Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects at least 18 years of age
* Subjects who in the opinion of the investigator based on medical history and physical exam can tolerate the PET scan procedures

Exclusion Criteria:

* Have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
* Have current clinically significant cardiovascular disease.
* Have a history of drug or alcohol abuse within the last year, or prior prolonged history of abuse
* Have a clinically significant infectious disease, including Acquired Immune Deficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV) infection or previous positive test for hepatitis
* Women of childbearing potential must not be pregnant (negative urine beta-hCG at the time of screening and negative urine beta-hCG on the day of imaging) or lactating at screening or at day of imaging
* Have a history of relevant severe drug allergy or hypersensitivity (Relevant severe drug allergies should be determined by the PI, and any questions about a subject's eligibility can be directed to Avid. If a subject has a history of severe drug allergies, it may be dangerous for them to participate in a study with a novel compound
* Have received an investigational medication within the last 30 days. Current clinically significant or unstable medical comorbidities, as indicated by history or physical exam
* Have received a radiopharmaceutical for imaging or therapy within the past 7 days prior to the imaging session for this study
* Body weight \> 300 pounds
* History of significant radiation exposure
* Participants with pacemakers, implanted electronic hearing devices, aneurysm clips, shrapnel, unallowed prosthetic or other metallic device in their bodies
* Pre-existing CNS disease (other than dementia), endocrine, or severe cardiovascular disease (MI, CABG, angioplasty)
Motivations to Transplant Registry Participation

The current study seeks to understand factors that influence college students' likelihood of participating the National Marrow Donor Program (NMDP)/Be the Match for bone marrow and stem cell donations. The secondary aim is to compare emotional and rational approaches to encouraging participation in the registry and how these approaches may impact intentions to participate in the NMDP.

This study is a randomized controlled trial that will randomize participants to receive either an emotional appeal about a child with cancer who needs a bone marrow transplant or a rational appeal using data on the racial/ethnic disparities within the transplant registry.

Participants will be recruited through the Psychology Subject Pool, which will then link students to the study measures in an online survey. Participants will be asked their age to confirm eligibility to participate (students must be between 18-35), and eligible students will be presented with the consent form through the online survey system. Participants will then be asked to complete measures of demographic information, personality/psychological characteristics, and transplant-related knowledge, intentions, and attitudes. All participants will then be given background information on bone marrow transplants.

Randomization: Students will be randomized by sex in the online survey system to the emotional presentation condition or the rational presentation condition. The emotional condition will tell the story of a fictional pediatric patient with cancer who needs a transplant. The rational condition will describe the facts about the need for diversity in the registry.

After being presented with the rational or emotional appeal, participants will again be asked about their intentions to register, their motivations for registering, and their mood.

Eligibility Criteria:
Inclusion Criteria:

* Rutgers Camden Students enrolled in Psych 101 and Method and Theory
* Between the ages of 18-35

Exclusion Criteria:

* Students under 18 years of age or over 36 or older will be excluded.
Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

This is a prospective,open-label, phase1/2 study to evaluate the safety and efficacy of anti-FLT3 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of FLT3 positive relapsed or refractory acute myeloid leukemia.

The patients will receive infusion of anti-FLT3 CAR T-cells targeting FLT3 to evaluate the safety and efficacy of anti-FLT3 CAR T-Cells in relapsed or refractory acute myeloid leukemia.

Eligibility Criteria:
Inclusion Criteria:

* FLT3 positive relapsed/refractory acute myeloid leukemia
* Age 16-65 years.
* Left ventricular ejection fractions ≥ 0.5 by echocardiography
* Creatinine \< 1.5x upper limit of normal.
* Aspartate aminotransferase/aspartate aminotransferase ≤ 2.5x upper limit of normal
* Total bilirubin ≤ 1.5x upper limit of normal
* Karnofsky performance status ≥ 60
* Expected survival time ≥ 3 months (according to investigator's judgement)

Exclusion Criteria:

* Patients are pregnant or lactating
* Uncontrolled active infection
* Grade III/IV cardiovascular disability according to the New York Heart
* Association Classification
* Active hepatitis B or hepatitis C infection
* Patients with HIV infection
* Patients with a history of seizure
* Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement)